A narcotics-law barrier blocks cannabidiol in the GCC, approved for only 40-50% of named-patient import applications, making stiripentol, with a 71% adjunct responder rate in STICLO, the de-facto Dravet standard of care instead.
Cannabidiol (Epidiolex, Jazz Pharmaceuticals), which delivered a 38.9% seizure-reduction result across the GWPCARE trials, is not registered in any GCC state as of this writing. Cannabis-derived products require an exceptional MOH/DHA import license under UAE and KSA federal narcotics law; approval runs at roughly 40-50% of applications at KFSH&RC and takes 3 to 6 months per patient, leaving only an estimated 30-50 patients across the entire GCC on named-patient compassionate use. Fenfluramine (Fintepla, UCB), which showed a 62% seizure-reduction result in the STUDIO trials and was EMA-approved in 2020, has SFDA registration pending and is limited to named-patient access at KFSH&RC and Aster DM centres, also requiring MOH exceptional import.
Stiripentol (Diacomit, Biocodex), which showed a 71% responder rate as adjunct therapy in the STICLO trial, is imported via Biocodex's GCC distributor and is by far the most widely used Dravet-specific agent in the region, purely because its regulatory pathway is simpler than cannabidiol's or fenfluramine's. The stiripentol-plus-valproate-plus-clobazam backbone is the dominant regimen at GCC specialist centres (KFSH&RC, AUH, Sidra Medicine), reversing the US/EU hierarchy in which cannabidiol is typically the first-choice add-on. This creates a fundamentally different competitive entry point for any new Dravet therapy: it competes against a stiripentol-anchored backbone, not against cannabidiol. Underlying diagnosis is also a bottleneck: SCN1A genetic testing is available at only KFSH&RC, AUH Genetics, Sidra Medicine, and roughly four other centres across the GCC, and an estimated 600 to 800 Dravet patients exist regionwide (1 in 15,700 applied to a roughly 12 million paediatric population) against fewer than 200 molecularly confirmed in registries, a diagnosis rate below 30% of true prevalence.
Dravet syndrome agents in the GCC — registration and access status, 2026
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Epidiolex (cannabidiol) | Phytocannabinoid — Schedule V analogue in GCC | Jazz Pharmaceuticals | Not registered in GCC as of this writing; requires exceptional narcotics-import license | GWPCARE1-4 — 38.9% seizure reduction | Not on any GCC formulary; named-patient compassionate use only, ~30-50 patients regionwide |
| Fintepla (fenfluramine) | Low-dose serotonin-releasing agent | UCB | EMA approved 2020; SFDA registration pending; limited GCC access | STUDIO 1 & 2 — 62% seizure reduction | Not on GCC formulary; named-patient access at KFSH&RC and Aster DM centres; MOH exceptional import required |
| Diacomit (stiripentol) | GABA-A positive allosteric modulator — adjunct | Biocodex | Available via GCC import; most accessible Dravet-specific agent | STICLO — 71% responder rate as adjunct | Imported via Biocodex GCC distributor; specialist prescription; de-facto GCC standard of care at KFSH&RC, AUH, Sidra Medicine |
Sources: KFSH&RC epilepsy genetics programme 2022; GCC paediatric neurology network data; KFSH&RC pharmacy formulary committee data 2023; MOH Saudi exceptional import process documentation; GCC paediatric neurology prescribing survey 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- MOH/DHA exceptional-import process and approval-rate benchmarking (40-50% at KFSH&RC)
- Narcotics-law barrier analysis specific to UAE/KSA federal law
- Named-patient compassionate-use precedent and patient volumes
- Regulatory-pathway resolution scenarios and first-mover commercial implications
Delivers
- Stiripentol + valproate + clobazam regimen prevalence at GCC specialist centres
- Comparative positioning strategy vs a stiripentol backbone rather than cannabidiol
- KFSH&RC, AUH, and Sidra Medicine prescribing-pattern data
- Fenfluramine's named-patient access pathway and adoption trajectory
Delivers
- SCN1A testing-centre mapping (KFSH&RC, AUH Genetics, Sidra Medicine, ~4 others)
- Prevalence modelling: 600-800 estimated vs <200 molecularly confirmed
- GCC paediatric neurology network diagnostic-pathway analysis
- Recommendations for genetic-testing access partnerships
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why stiripentol, not cannabidiol, anchors GCC prescribing, the reverse of the US/EU treatment hierarchy
- How KFSH&RC, AUH, and Sidra Medicine specialist centres set the de-facto regional standard of care
- Trial-result comparison: 38.9% seizure reduction for cannabidiol (GWPCARE) vs 62% for fenfluramine (STUDIO) vs 71% responder rate for stiripentol (STICLO)
- Company and mechanism profiles for Jazz Pharmaceuticals' cannabidiol, UCB's fenfluramine, and Biocodex's stiripentol
- Why SCN1A testing access at roughly 7 centres regionwide caps confirmed diagnoses below 200 of an estimated 600-800 patients
- Mapping the diagnostic gap across KFSH&RC, AUH Genetics, and Sidra Medicine against a sub-30% true-prevalence diagnosis rate
- How UAE and KSA federal narcotics law forces cannabidiol through an exceptional MOH/DHA import license rather than standard registration
- Why the named-patient approval process clears only 40-50% of applications and takes 3-6 months per patient at KFSH&RC
- The stiripentol-plus-valproate-plus-clobazam regimen that dominates prescribing at GCC specialist centres
- How Biocodex's simpler distributor-based import pathway made stiripentol the region's default Dravet therapy
- The paediatric neurology centres shaping GCC Dravet care: KFSH&RC, AUH, and Sidra Medicine
- How the GCC paediatric neurology prescribing survey 2023 maps referral and treatment patterns regionwide
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (SFDA and MOH programme documentation), peer-reviewed trial data, and GCC-specific registry and prescribing-survey data — not secondary summaries. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
GCC Dravet Syndrome CI sources: the KFSH&RC epilepsy genetics programme 2022, the GCC paediatric neurology network data, KFSH&RC pharmacy formulary committee data 2023, MOH Saudi exceptional import process documentation, and the GCC paediatric neurology prescribing survey 2023.
- Drug registration and named-patient access status verified against MOH Saudi exceptional import process documentation and KFSH&RC pharmacy formulary committee data 2023
- Clinical trial results verified against published GWPCARE, STUDIO, and STICLO trial data
- Dravet prevalence and SCN1A testing-capacity figures verified against the KFSH&RC epilepsy genetics programme 2022 and GCC paediatric neurology network data
- Stiripentol-backbone prescribing pattern verified against the GCC paediatric neurology prescribing survey 2023
Frequently asked questions
Commission this brief
AXLRx delivers GCC Dravet syndrome competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams entering the Gulf. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.